display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic, hormone-sensitive prostate cancer
metastatic, hormone-sensitive prostate cancer
androgen deprivation therapy (ADT)
abiraterone plus ADT LATITUDE STAMPEDE abiraterone
abiraterone plus docetaxel plus ADT PEACE-1
apalutamide plus ADT TITAN
darolutamide plus doxetaxel plus ADT ARASENS
docetaxel plus ADT GETUG-AFU 15 STAMPEDE docetaxel NCI E3805 ... CHAARTED
enzalutamide
enzalutamide plus ADT ENZAMET ARCHES

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons